Qiming Venture Partners
VC Fund
Shanghai, China
Qiming Venture Partners is a VC fund in Shanghai focused on Health Care and Biotechnology. Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
- Total investments:
- 905
- Last investment:
- Lead investor:
- 45%
- Fund size:
- $887M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Qiming Venture Partners invests in
Stages Qiming Venture Partners invests in
Countries Qiming Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $5M–$67M
- Series B
- $9.4M–$100M
- Series C
- $15M–$134M
Investment Focus
Industry
- Health Care 109 (12%)
- Biotechnology 94 (10%)
- Medical 90 (10%)
- Pharmaceutical 46 (5%)
- Artificial Intelligence 45 (5%)
Stage
- Series B 175 (19%)
- Series A 162 (18%)
- Series C 94 (10%)
- Seed 52 (6%)
- Series D 42 (5%)
Country
- China 333 (37%)
- United States 48 (5%)
- Hong Kong 11 (1%)
- Singapore 6 (1%)
- Indonesia 3 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Grace Lee
Partner & CFO
|
Partner & CFO | Total investments: 0 | Find email | |
Jinda Gao
Principal
|
Principal | Total investments: 11 | Find email | |
Oscar Zhang
Principal
|
Principal | Total investments: 27 | Find email | |
Shiyu Wang
Partner
|
Partner | Total investments: 13 | Find email | |
Alexander Sinclair-Wilson
Principal
|
Principal | Total investments: 4 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Blue Emergence
|
Blue Emergence is a marine technology consumer products company, | Angel / Jul 24, 2026 | |
Fibrox
|
Fibrox develops innovative cell therapies based on fibroblasts and clinical requirements for patients. | $3.7M / Series A / Jul 21, 2026 | |
Mufan Power
|
Mufan Power is a new energy high-tech enterprise in the field of turbomachinery. It is committed to the development of a new generation of zero-carbon hydrogen power generation technologies and products. Its main products are hydrogen gas turbines, which can be used in distributed energy and data centers. , rail transit, ship power, vehicle power,energy storage peak shaving and other carbon neutral scenarios. | Series C / Jul 13, 2026 | |
Tianhu Technology
|
Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. | Series A / Jul 13, 2026 | |
Kling AI
|
Kling AI is an AI-powered creative studio for creating imaginative images and videos, based on state-of-the-art generative AI methods. | $2.8B / Venture - Series Unknown / Jul 01, 2026 | |
|
Dongsheng Fusion
|
Dongsheng Fusion is a magnetic confinement fusion technology company that develops miniaturized fusion power plant technology. | $100M / Seed / Jun 08, 2026 | |
|
Dongsheng Fusion
|
Dongsheng Fusion is a magnetic confinement fusion technology company that develops miniaturized fusion power plant technology. | Seed / May 27, 2026 | |
Makera
|
Makera is essentially creating a maker's dream CNC machine; we use it every day for various projects and enjoy the experience, and we hope you will too. | $14.7M / Series A / May 06, 2026 | |
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | |
Microtide Biotechnology
|
Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M / Series A / Apr 29, 2026 | |
| See all 905 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Qiming Venture Partners invest in?
Qiming Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 905 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Qiming Venture Partners's check size?
Qiming Venture Partners typically joins rounds of $5M–$67M at Series A, $9.4M–$100M at Series B and $15M–$134M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Qiming Venture Partners participates in.
How do I contact Qiming Venture Partners?
Public channels for Qiming Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Qiming Venture Partners?
The team at Qiming Venture Partners includes Grace Lee (Partner & CFO), Jinda Gao (Principal) and Oscar Zhang (Principal), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
